Peptide antiestrogen compositions and methods for treating breast cancer
AssigneeUniversity of California
InventorRichard J. Pietras
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions comprising native, site-specifically mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator, and nucleic acid compositions encoding these polypeptide compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers, the preparation of pharmaceutical compositions, diagnostic kits, and the development of related assays for use in antitumor therapies.
Claims40
A composition comprising an isolated peptide of sequence SEQ ID NO:39.
A composition comprising an isolated peptide of between five and about 25 amino acid residues in length, wherein said peptide includes within its sequence an amino acid sequence represented by Leu-AA1-Asp-Leu-Leu, wherein AA1 is phosphotyrosine, or malonyltyrosine.
A method of treating a cancer cell, comprising delivering to a cancer cell a composition comprising an isolated peptide of between five and about 25 amino acid residues in length, wherein said peptide includes within its sequence an amino acid sequence represented by Leu-AA1-Asp-Leu-Leu, wherein AA1 is phosphotyrosine, or malonyltyrosine, whereby said composition decreases cell growth.
A method of treating a cancer cell, comprising delivering a composition comprising an isolated peptide of 25 amino acids in length or less having the amino acid sequence of SEQ ID NO:39 to a cancer cell, whereby said composition decreases cell growth.
A kit comprising, in suitable container means, a pharmaceutically-acceptable diluent and a therapeutically-effective amount of a composition comprising an isolated peptide of SEQ ID NO:39;
- or comprising an isolated peptide of between five and about 25 amino acid residues in length, wherein said peptide includes within its sequence an amino acid sequence represented by Leu-AA1-Asp-Leu-Leu, wherein AA1 is phosphotyrosine, or malonyltyrosine.
A method of killing a cancer cell, comprising providing to a cancer cell a therapeutically-effective amount of a composition comprising an isolated peptide of SEQ ID NO:39, or comprising an isolated peptide of between five and about 25 amino acid residues in length, wherein said peptide includes within its sequence an amino acid sequence represented by Leu-AA1-Asp-Leu-Leu, wherein AA1 is phosphotyrosine, or malonyltyrosine, whereby said composition kills said cell.
A method for treating cancer in an animal, comprising administering to an animal with cancer, a therapeutically effective amount of a composition comprising an isolated peptide of SEQ ID NO:39;
- or comprising an isolated peptide of between five and about 25 amino acid residues in length, wherein said peptide includes within its sequence an amino acid sequence represented by Leu-AA1-Asp-Leu-Leu, wherein AA1 is phosphotyrosine, or malonyltyrosine, whereby said composition inhibits cancer cell growth.
A method of treating cancer in an animal, said method comprising the steps of:
- (a) identifying an animal having increased estrogen receptor activity;
- and
- (b) administering to said animal a therapeutically-effective amount of a composition comprising an isolated peptide of SEQ ID NO:39;
- or comprising an isolated peptide of between five and about 25 amino acid residues in length, wherein said peptide includes within its sequence an amino acid sequence represented by Leu-AA1-Asp-Leu-Leu, wherein AA1 is phosphotyrosine, or malonyltyrosine, whereby said composition decreases cancer cell growth.
Dependencies are inferred from the claim text.